Publications
Publications
- April 2018
- HBS Case Collection
Celgene
By: Malcolm Baker and Emily R. McComb
Abstract
In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene’s key drug, Revlimid. In response, Celgene’s share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial investment.
Keywords
Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis
Citation
Baker, Malcolm, and Emily R. McComb. "Celgene." Harvard Business School Spreadsheet Supplement 218-743, April 2018.
About The Authors
